India's Department of Industrial Policy and Promotion (DIPP) is at it again -- potentially. The group is looking at whether BMS' CML cancer drug dasatinib should lose its patent protections due to "emergency" conditions in the market. That means that consumers in the market think it is too expensive. This would just be the latest chapter in India invalidating a Western company's patent to allow its production by a cheaper local company.
For their part, BMS and Pfizer have had enough. They have been pressuring US officials to put India on a watch list for countries who don't respect patent laws and therefore receive much greater scrutiny. If the Indian government's plan goes through. It will be the first time that "emergency provisions" have been invoked.
In the very recent past, the following Western drugmakers have fallen into similar straights with India -- which seems particularly prevalent with oncology drugs -- GSK (Tykerb), Bayer (Nexavar), Novartis (Gleevec), and Roche (Pegasys and now Herceptin dispute). Thus, BMS and Pfizer's request for India's elevated (demoted) status on a Watch List. See The Economic Times.
Posted by Bruce Lehr May 5th 2014.